Jagiellonian University Medical College, Department of Metabolic Diseases, Krakow 30-688, Poland; University Hospital in Krakow, Krakow 30-688, Poland.
Medtronic International Trading Sàrl, Medtronic Diabetes, Switzerland.
Diabetes Res Clin Pract. 2024 Oct;216:111832. doi: 10.1016/j.diabres.2024.111832. Epub 2024 Aug 22.
The aim of the study was to analyze the real-world performance of MiniMed 780G (MM780G) Advanced Hybrid Closed Loop (AHCL) system users from Poland (PL) and compare it to the European region excluding Poland (EU-PL) in order to identify factors contributing to potential differences. The former achieved some of the best Time in Range (TIR) results globally using this technology.
CareLink Personal data uploaded by MM780G system users from August 2020 to December 2022 were analyzed.
The Polish users (N=1304) on average reached to TIR of 79.1 ± 8.7 % (vs 73.0 ± 10.0 % for EU-PL, N=55659), a TBR<54 mg/dL of 0.6 ± 0.7 % (vs 0.4 ± 0.6 %) and a TBR<70 mg/dL of 2.9 ± 2.1 % (vs 2.1 ± 1.8 %). The adoption rate of optimal settings (i.e, GT=100 mg/dL, AIT=2hr) in PL was high (19.7 % vs 6.3 %), and filtering on optimal setting users led to less pronounced differences in glycemic control between PL and EU-PL. A univariable analysis with post-AHCL TIR showed that geography itself (PL vs EU-PL) is not a significant contributor to a high post-AHCL TIR (p = 0.15), and that much of the Polish post-AHCL TIR can be explained by the high pre-AHCL TIR.
The Polish MM780G users achieved better glycemic control than the general European population (excluding Poland). This is largely attributable to the adoption of optimal settings in Poland and the already high glycemic outcomes at system start. As these characteristics can be implemented elsewhere, we believe this outstanding result can be obtained in other countries as well.
本研究旨在分析波兰（PL）和欧洲（EU-PL，不包括波兰）的 MiniMed 780G（MM780G）高级混合闭环（AHCL）系统用户的真实世界表现，以确定导致潜在差异的因素。该地区的用户曾使用该技术取得了全球最佳时间范围内（TIR）的结果。
分析了 2020 年 8 月至 2022 年 12 月期间 MM780G 系统用户上传的 CareLink 个人数据。
波兰用户（N=1304）的 TIR 平均达到 79.1±8.7%（EU-PL 为 73.0±10.0%，N=55659），TBR<54mg/dL 的比例为 0.6±0.7%（EU-PL 为 0.4±0.6%），TBR<70mg/dL 的比例为 2.9±2.1%（EU-PL 为 2.1±1.8%）。波兰的最佳设置（即 GT=100mg/dL，AIT=2 小时）采用率很高（19.7% vs 6.3%），对最佳设置用户进行筛选后，PL 和 EU-PL 之间的血糖控制差异不那么明显。对 AHCL 后 TIR 的单变量分析表明，地理位置（PL 与 EU-PL）本身并不是 AHCL 后 TIR 高的重要因素（p=0.15），而波兰 AHCL 后 TIR 的大部分可以用 AHCL 前 TIR 高来解释。
波兰的 MM780G 用户的血糖控制优于欧洲一般人群（不包括波兰）。这在很大程度上归因于波兰采用了最佳设置，以及系统启动时已经较高的血糖水平。由于这些特点可以在其他地方实施，我们相信在其他国家也可以取得如此出色的结果。
